Alpha 2.0
Login Register
» Articles » PMID: 35759726

Circulating Tumor Cell Burden As a Component of Staging in Multiple Myeloma: Ready for Prime Time?

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2022 Jun 27
PMID 35759726
Authors
Rajshekhar Chakraborty
Suzanne Lentzsch
Affiliations
Soon will be listed here.
Citing Articles

A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival.

Li F, Li J, Yuan Y, Zhang H, Zhang S, Bian L Heliyon. 2024; 10(7):e29217.

PMID: 38623216 PMC: 11016733. DOI: 10.1016/j.heliyon.2024.e29217.

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant.

Tembhare P, Sriram H, Khanka T, Gawai S, Bagal B, Ghogale S Hemasphere. 2024; 8(4):e63.

PMID: 38566804 PMC: 10983024. DOI: 10.1002/hem3.63.

Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma.

Ikeda D, Terao T, Oura M, Uehara A, Tabata R, Narita K Blood Adv. 2023; 8(1):37-46.

PMID: 38150271 PMC: 10784675. DOI: 10.1182/bloodadvances.2023011890.

Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients.

Zhao H, Wang L, Fang C, Li C, Zhang L Front Oncol. 2023; 13:1272788.

PMID: 38090481 PMC: 10711619. DOI: 10.3389/fonc.2023.1272788.

More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.

Tian M, Liang X, Xu W, Yi X, Yue T, Zhang Y Ann Hematol. 2023; 102(10):2943-2945.

PMID: 37434095 DOI: 10.1007/s00277-023-05362-8.